VolitionRX Limited

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited 3rd Quarter 2023 Earnings Conference Call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be open for questions. If you have a question, please press the star key followed by the number 1 on your touchtone phone. If you would like to withdraw your question, please press the star 2 key followed by the number 2 on your touchtone phone. If you're using speaker equipment, please lift the handset before making your selection. This conference is being recorded today, November 15, 2023. I'd now like to turn the conference call over to Scott Powell, Executive Vice President of Investor Relations. Please go ahead.

Thank you, and welcome everyone to today's earnings conference call for VolitionRx Limited. This call will cover Volition's financial and operating results for the third quarter of 2023, along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question and answer session. Also on our call today are Mr. Cameron Reynolds, President and Group Chief Executive Officer, Mr. Terry Cuse, Group Chief Financial Officer, Dr. Tom Butera, Chief Executive Officer of our Volition Veterinary Subsidiary, and Dr. Andrew Retter, Medical Consultant to Volition. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward looking statements made during the course of this call. I would now like to turn the call over to our president and group chief executive officer, Mr. Cameron Reynolds.

Cameron? Thanks, Scott, and thank you, everyone, for joining Volition's third quarter 2023 earnings call today. We especially appreciate your time, given this is the busy earnings call season. We will commence the call with a financial report from our group chief financial officer, Terry Hughes, before moving to Dr. Tom Butera, our Chief Executive Officer of Volition Veterinary, for an update on the rollout of our NUQ Vet Cancer Test. And then I'm delighted that Dr. Andy Retter, who works as a haematologist and intensive care consultant at one of the UK's leading hospitals, has pre-recorded his thoughts on our progress in our NUQ NETS pillar. And in particular, the result of our FDA meeting, achieving a clear regulatory pathway. And also of our recent breakthrough early cancer detection method, recently presented at ESMO in October. I will wrap up with my thoughts and upcoming milestones and discuss our overall strategy going forward. Without further ado, I'll hand you across to Tereg for the financial report.